Zynex Reports Major Losses and Revenue Decline Amid Payment Suspension Challenges in Q2 2025

Zynex, Inc. (OTCMKTS: ZYXI) reported significant developments and challenges in its recent quarterly results ending June 30, 2025. The company operates primarily in the medical device industry, focusing on electrotherapy and pain management products.

Key Highlights:

• Net Revenue: $22.29 million for Q2 2025, down 55% from $49.88 million in Q2 2024.
• Net Loss: $20.03 million in Q2 2025, compared to a net income of $1.22 million in Q2 2024.
• Operating Expenses: Increased overall; total costs of revenue and operating expenses amounted to $32.57 million, exceeding revenue for the quarter.
• Tricare Payment Suspension: Temporarily halted payments, causing significant revenue loss; historically represented 20-25% of company revenue.
• Restructure Efforts: Workforce reduced by 14% (86 roles) to save approximately $5 million annually in response to declining revenues.
• Convertible Senior Notes: Outstanding $60 million notes due May 2026, raising concerns about liquidity.

Positive Aspects:

• Relatively steady cash reserves of $17.54 million as of June 30, 2025.
• Continued operation of the Zynex Medical and Zynex Monitoring Solutions subsidiaries, facilitating innovative product development.
• Implementation of cost-cutting measures aimed at stabilizing finances and improving profitability.

Negative Aspects:

• Significant drop in total revenue year-over-year (49% decrease for the first half of 2025).
• Loss of key government payer revenue due to ongoing investigations and claims issues.
• Sustained net losses, facing potential bankruptcy concerns pending the outcome of Tricare discussions and financing capabilities.
• Material weakness in internal controls identified, raising risks for future financial reporting accuracy.

This latest quarter has posed severe challenges for Zynex, Inc., particularly in terms of revenue generation and operational stability. Given the significant shifts in financial metrics and ongoing issues with payment suspensions, the company will need solid strategic moves to navigate through these turbulent conditions. Investors should remain cautious and closely watch upcoming developments, including management changes, litigation outcomes, and financial health indicators.